Visen Pharmaceuticals held its Annual General Meeting on 27 June 2025. During the meeting, several proposals were presented and approved. The audited consolidated financial statements for the year ended 31 December 2024, along with the reports of the directors and auditors, were received. Mr. LU An-Bang was re-elected as an executive director. Additionally, the commercial supply framework agreement between Visen Pharmaceuticals HK Limited and Ascendis Pharma Europe A/S, including the transactions and proposed annual caps related to it, was approved.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Visen Pharmaceuticals published the original content used to generate this news brief on June 27, 2025, and is solely responsible for the information contained therein.